Oncotelic Therapeutics' 45% Ownership in JV Partner GMP Bio Set to Receive Major Fair-Value Update

Oncotelic Therapeutics Inc. (OTCQB: OTLC) is preparing for a major fair-value update on its 45% ownership in JV partner GMP Bio, following a new independent assessment pointing to a substantial increase in the asset's worth. This development reinforces Oncotelic Therapeutics' position as a treatment leader in the oncology space, alongside companies like Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), and Eli Lilly. The fair-value adjustments under U.S. GAAP are seen as meaningful signals of real scientific and business advancement, translating research achievements into quantifiable economic impact.